ABC | Volume 111, Nº6, Dezembro 2018

Minieditorial Carvalho et al A cistatina C poderia prever desfechos cardiovasculares? Arq Bras Cardiol. 2018; 111(6):808-809 1. Bots ML, Groenewegen KA, Anderson TJ, Britton AR, Dekker JM, Engström G, et al. Common carotid intima-media thickness measurements do not improve cardiovascular risk prediction in individuals with elevated blood pressure: the USE-IMT collaboration. Hypertension 2014; 63(6):1173-81. 2. Possner M, Liga R, Gaisl T, Vontobel J, Clerc OF, Mikulicic F, et al. Quantification of epicardial and intrathoracic fat volume does not provide an added prognostic value as an adjunct to coronary artery calcium score and myocardial perfusion single-photon emission computed tomography. Eur Heart J Cardiovasc Imaging 2016;17(8):885-91. 3. Mortensen MB, Afzal S, Nordestgaard BG, Falk E. The high-density lipoprotein-adjusted SCOREmodel worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study. Eur Heart J. 2015;36(36):2446-53. 4. Mahabadi AA, Mohlenkamp S, Lehmann N, Kälsch H, Dykun I, Pundt N, et al; Heinz Nixdorf Recall Study Investigators. CAC score improves coronary andCVriskassessmentabovestatin indicationbyESCandAHA/ACCprimary prevention guidelines. JACC Cardiovasc Imaging. 2017;10(2):143-53. 5. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012;33(10):1190-200. 6. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049-60. 7. Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, Giannone R, et al. Cystatin C and contrast-induced acute kidney injury. Circulation. 2010;121(19):2117-22. 8. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, PoniatowskiB,PawlakK,DobrzyckiS.NGAL(neutrophilgelatinase-associated lipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine? Int J Cardiol. 2008;127(2):290-1. 9. Einwoegerer CF, Domingueti CP. Association between increased levels of cystatin C and the development of cardiovascular events or mortality: a systematic review and meta-analysis. Arq Bras Cardiol. 2018; 111(6):796-807. 10. Woitas RP, Kleber ME, Meinitzer A, Grammer TB, Silbernagel G, Pilz S, et al. CystatinC is independentlyassociatedwithtotalandcardiovascularmortality in individuals undergoing coronary angiography. The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Atherosclerosis. 2013;229(2):541-8. 11. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/ AmericanHeart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73. Erratum in: Circulation. 2014;129(25 Suppl 2):S74-5. 12. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the FraminghamHeart Study. Circulation. 2008;117(6):743-53. 13. van der Laan SW, Fall T, Soumare A, Teumer A, Sedaghat S, Baumert J, et al. Cystatin C and cardiovascular disease: a Mendelian Randomization study. J Am Coll Cardiol. 2016;68(9):934-45. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 809